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Sexually Transmitted Bedfellows: Exquisite Association 
Between HIV and Herpes Simplex Virus Type 2 in 21 
Communities in Southern Africa in the HIV Prevention 
Trials Network 071 (PopART) Study
John Bradley,1 Sian Floyd,1 Estelle Piwowar-Manning,4 Oliver Laeyendecker,5 Alicia Young,6 Nomtha Bell-Mandla,7 Justin Bwalya,8  
Peter Bock,7 Sarah Fidler,3 Helen Ayles,2,8 and Richard J. Hayes,1 on behalf of the HPTN 071 (PopART) Study Team
1MRC Tropical Epidemiology Group and 2Department of Clinical Research, London School of Hygiene and Tropical Medicine, and 3HIV Clinical Trials Unit, Department of Medicine 
Imperial College London, United Kingdom; 4HIV Prevention Trials Network Laboratory Center, Johns Hopkins University School of Medicine, and 5Laboratory of Immunoregulation, 
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland; 6Vaccine and Infectious Disease Division, Fred Hutchinson Cancer 
Research Center, Seattle, Washington, USA; 7Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Parow, South Africa; and 8Zambart, 
University of Zambia School of Medicine, Lusaka
Background. Human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV2) are strongly associated, although 
mechanisms are not fully understood. An HIV prevention trial allowed reexamination of this association at individual and commu-
nity levels.
Methods. The HIV Prevention Trials Network 071 (PopART) study evaluates a combination prevention intervention in 21 
urban communities in Zambia and South Africa. To measure impact on HIV infection incidence, a cohort of approximately 2000 
adults (age range, 18–44 years) was selected randomly from each community. Baseline data on sociodemographic characteristics, 
behavior, and HIV/HSV2 serologic findings were used to examine the association between HIV and HSV2. At the community level, 
HIV prevalence was plotted against HSV2 prevalence.
Results. A total of 38 691 adults participated. HSV2 prevalence among women and men was 50% and 22%, respectively, in 
Zambia and 60% and 27%, respectively, in South Africa. Estimated HSV2 infection incidence among those aged 18–24 years was 
8.06 cases/100 person-years (95% confidence interval [CI], 6.76–9.35) and 1.76 cases/100 person-years (95% CI, 1.30–2.22) among 
women and men, respectively. A 6-fold higher odds of HIV infection was seen in HSV2-infected individuals in both sexes, after 
adjustment for confounders (odds ratio, 6.66 [95% CI, 6.07–7.31] among women and 6.57 [95% CI, 5.56–7.77] among men). At the 
community-level, there was a strong linear relationship between HIV and HSV2 prevalence (ρ = 0.92; P < .001).
Conclusions. There was an exquisite association between these 2 infections, at the individual and community levels, likely due in 
part to a powerful cofactor effect of HSV2 on HIV transmission. HSV2 control could contribute to HIV prevention.
Keywords. HIV; HSV2; South Africa; Zambia; cofactor; urban; ecological analysis.
 
Herpes simplex virus type 2 (HSV2) is the main cause of gen-
ital herpes and the most common sexually transmitted virus 
worldwide, with an estimated 417 million infections in adults 
aged 15–49  years [1]. Overall estimates of the prevalence of 
infection in different populations are difficult to compare and 
interpret because HSV2 is a lifelong incurable infection and has 
a prevalence that increases with age. Nevertheless, it is clear that 
prevalence varies substantially between regions and countries, 
presumably reflecting varying patterns of sexual behavior that 
are, in turn, determined by underlying demographic, social, 
and economic factors [1]. Worldwide prevalence among adults 
aged 15–49  years is estimated at 11%, with values of 7% in 
Europe, 14% in the Americas, and 32% in Africa [1]. Studies 
in sub-Saharan Africa have shown that the HSV2 prevalence is 
low before the age of sexual debut; increases rapidly during ado-
lescence and early adulthood, with a higher prevalence among 
young women than among young men; and plateaus at 70%–
80% in both sexes after 30 years of age [2–4].
A remarkably consistent finding has been the close epidemi-
ological association between HSV2 and HIV. A meta-analysis of 
longitudinal studies showed a 3-fold increase in the risk of HIV 
acquisition in individuals with HSV2 infection [5], and there 
is evidence of a stronger cofactor effect in those in the early, 
more symptomatic phases of HSV2 infection [6–9]. Moreover, 
HSV2 in individuals who are already infected with HIV seems 
to increase the shedding of HIV, possibly resulting in a greater 
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risk of HIV transmission to sex partners [10, 11]. Modeling 
studies have shown that HSV2 may have played an important 
role in facilitating the spread of HIV in sub-Saharan Africa [12, 
13], and an ecological study in 4 cities with contrasting HIV 
epidemics identified differences in HSV2 prevalence as one of 
the main factors that might help to explain differences in HIV 
prevalence [4, 14, 15].
There is a strong biological rationale for a facilitating effect 
of HSV2 on HIV transmission, owing to the episodic genital 
lesions associated with herpes, as well as subtler effects at the 
cellular level that may persist while HSV2 is asymptomatic [16]. 
Moreover, HSV2 infection results in an increase in the density 
of target cells for HIV in the male foreskin [17]. However, a 
series of randomized trials of acyclovir treatment in those with 
HSV2 infection found no evidence of an effect on HIV acquisi-
tion or transmission, probably because the treatment provided 
was insufficient to control the expression of HSV2 and avert its 
potentiating effect on HIV infection [18–20]. Work is now in 
progress on the development and evaluation of HSV2 vaccines, 
motivated both by a need to reduce the burden of ill health asso-
ciated with genital herpes and to establish a potential strategy to 
prevent HIV acquisition [21–24].
A large community-randomized trial of an HIV combina-
tion prevention intervention offered an opportunity to reeval-
uate the association between HIV and HSV2 in large urban and 
peri-urban settlements in Southern Africa. The HIV Prevention 
Trials Network (HPTN) 071 (PopART) study is evaluating the 
impact of an intervention involving universal testing and treat-
ment on the incidence of HIV infection at the population level 
in 21 communities in Zambia and South Africa [25]. We have 
used baseline data from the nearly 40 000 adults in this trial, to 
measure the association between the 2 infections at individual 
level, and also in an ecological analysis at the community level.
METHODS
Study Design
Full details of the HPTN 071 (PopART) trial have been pre-
sented previously [25]. In brief, 21 urban and peri-urban com-
munities in Zambia and South Africa (each community was 
defined as the catchment population of a health facility) have 
been randomly allocated to 3 study arms. Arm A is receiving the 
full PopART intervention, which comprises universal annual 
home-based HIV testing and counseling provided by lay com-
munity health workers, who also assist with referral, linkage to 
care, and adherence support for clients who need HIV-related 
services, in addition to the offer of immediate initiation of anti-
retroviral therapy (ART) irrespective of CD4+ T-cell count at 
the local clinic. Arm B is receiving the full PopART interven-
tion except that ART is provided according to current national 
treatment guidelines. Arm C is a control arm that continues 
to receive current national standard of care. During 2016, all 
arm B and C clinics transitioned to providing ART irrespec-
tive of CD4+ T-cell count, in accordance with changing national 
guidelines.
The impact of the PopART intervention on HIV infection 
incidence is being measured in a population cohort comprising 
a random sample of adults from the general population, who 
will be followed up annually for 36 months. A brief census was 
performed in each community prior to the trial and was used to 
select a random sample of households. With the agreement of 
the household head, all adults aged 18–44 years residing in each 
selected household were enumerated, and one was selected at 
random for enrollment in the population cohort, with an initial 
target of 2500 adults in each community. Data for the analysis 
presented in this article came from the baseline survey of the 
population cohort, which was performed between November 
2013 and March 2015.
Following informed consent, data on sociodemographic, 
behavioral, and other variables were collected from population 
cohort participants, using an interviewer-administered ques-
tionnaire on a handheld electronic-data-capture device. At the 
end of the interview, a blood sample was collected by a trained 
research nurse and transported to the laboratory for processing, 
storage, and analysis. The participant was informed that test-
ing would be performed at a later date for research purposes 
and that results would not be returned, but for those wishing to 
know their HIV status the nurse offered an on-the-spot rapid 
HIV test, using a finger-prick blood sample.
Laboratory Methods
HIV and HSV2 status were determined by testing blood 
samples collected from consenting survey participants. To 
determine HIV status, blood samples underwent in-country 
analysis by a single fourth-generation assay (Architect HIV Ag/
Ab Combo Assay, Abbott Diagnostics, Delkenheim, Germany). 
Further testing was performed at the HPTN Laboratory Center 
(Baltimore, MD). Samples that had reactive results of in-coun-
try analysis were tested with a second fourth-generation assay 
(GS HIV Combo Assay, Bio-Rad Laboratories, Redmond, WA). 
Samples with discrepant/discordant test results were tested 
with additional assays to determine HIV status. For HSV2 
status, blood samples underwent in-country analysis by the 
Kalon HSV2 immunoglobulin G enzyme-linked immunosor-
bent assay (ELISA; Kalon Biological, United Kingdom), where 
the in-country laboratories’ performance was validated by the 
HPTN laboratory core [26]. The manufacturer’s calibrator was 
run in duplicate on all plate runs in the study and OD units 
from the ELISA plates were converted to index values. The 
manufacturer’s index value cutoffs (<0.9, negative; 0.9–1.1, 
indeterminate; and >1.1, positive) were used to assign sample 
results. For the current study, samples with an indeterminate 
result were considered negative for HSV2.
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Statistical Methods
Data from the baseline survey of the population cohort were 
first used to present the overall prevalence of HSV2 by age and 
sex in each country. The incidence of HSV2 infection in the 
group aged 18–24  years was estimated from the age-specific 
seroprevalence, assuming a constant rate of seroconversion. The 
probability of being seropositive at age A was assumed to be 
k + [1 − k][1 − e−λ(A − 18)], where λ is the seroconversion rate and 
k is the seroprevalence at age 18 years. To account for cluster-
ing, a community-level, normally distributed random effect was 
added on the logit scale. Estimation was performed using the 
maximum likelihood method.
Next we performed logistic regression analysis to explore 
risk factors for HSV2 infection at the individual level, stratified 
by sex, with adjustment for age group and study community. 
A hierarchical approach was used for model fitting [27], with 
the effects of sociodemographic variables adjusted for other 
sociodemographic variables and the effects of behavioral and 
biological variables adjusted for all other variables. We tested 
for interactions between country and each variable to assess 
whether associations were similar in Zambia and South Africa. 
We then examined the association between HSV2 and HIV 
infection at the individual level, adjusting for age group, sex, 
study community, and all other variables that were confounding 
factors for this association.
Finally, we performed an ecological analysis to explore the 
association between HIV prevalence and HSV2 prevalence 
at the population level. We plotted the community-level HIV 
prevalence against the community-level HSV2 prevalence. 
We also examined whether differences in HSV2 prevalence 
across communities could be explained on the basis of mea-
sured behavioral or other variables.
Ethical Considerations
All participants in the population cohort gave written informed 
consent. The study and all of the procedures described above 
were approved by the ethics committees of the London School 
of Hygiene and Tropical Medicine, the University of Zambia, 
and Stellenbosch University.
RESULTS
A total of 38 691 adults aged 18–44  years were enrolled in 
the population cohort during the baseline survey (19 750 in 
Zambia and 18 941 in South Africa), which was 74% of the tar-
get number of 52 500. Numbers enrolled per community var-
ied from 1007 to 2559 individuals. A  complete questionnaire 
was completed and a blood specimen was collected for 36 954 
participants (96%). Laboratory results for HSV2 infection and 
confirmed HIV status were available for 37 284 participants 
(96%) and 37 334 participants (96%), respectively.
HSV2 Prevalence by Age, Sex, and Country
The overall prevalence of HSV2 infection among women and men 
was 50% and 22%, respectively, in the 12 Zambian communities 
and 60% and 27%, respectively, in the 9 South African commu-
nities. Prevalence by age, sex, and country is shown in Figure 1 
and Supplementary Table 1. Prevalence increased steeply with 
age and was consistently higher in women than men in every 
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Figure 1.  Herpes simplex virus type 2 (HSV2) prevalence, by sex, country, and age group, in all age groups (left) and those aged <25 years (right).
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy178/4962568
by London School of Hygiene & Tropical Medicine user
on 25 April 2018
4 • JID 2018:XX (XX XXXX) • Bradley et al
age group in both countries. HSV2 prevalence was already very 
high in women aged 18–24 years (29% in Zambia and 38% in 
South Africa), increasing to over 70% by age 35 years. In men, 
HSV2 prevalence was much lower in the youngest age group (7% 
in Zambia and 9% in South Africa), increasing to around 50% 
in men aged ≥35 years. Figure 1 also shows the prevalence by 
year of age among men and women aged 18–24 years. Around 
20% of 18-year-old women in South Africa were infected with 
HSV2, compared with 13% in Zambia, but in both countries the 
prevalence increased to >40% by age 24 years. Prevalence was 
much lower in men aged 18 years (5% in South Africa and 4% 
in Zambia). The incidence in the group aged 18–24 years was 
estimated to be 8.06 cases/100 person-years (95% confidence 
interval [CI], 6.76–9.35) and 1.76 cases/100 person-years (95% 
CI, 1.30–2.22) among women and men, respectively.
Risk Factors for HSV2 Infection
Table  1 shows associations between sociodemographic and 
behavioral/biological variables and HSV2 infection separately 
for men and women (data are from both countries combined). 
After adjustment for age, community, and other factors, asso-
ciations with several of the variables examined were observed 
in both sexes. HSV2 prevalence increased with lower levels 
of education, more nights spent away from home, and lower 
socioeconomic status and was higher among those who were 
widowed, divorced, or separated. It also increased steeply 
with reported lifetime number of sex partners and was higher 
among those with a high Audit score, indicating possible alco-
hol dependence. Among women but not men, the HSV2 prev-
alence increased among those with a younger age at first sex 
and those who reported use of condoms at last sex. There were 
also associations with ethnic group, but a large number of eth-
nic groups were represented, and these associations were quite 
strongly confounded with study community. These effects of 
ethnic group are not presented or discussed further.
The association of 3 variables with HSV2 differed significantly 
by country (Supplementary Tables  2 and 3). In South Africa, 
there was evidence that HSV2 infection was more prevalent 
among men who had undergone traditional circumcision than 
among those who were uncircumcised or who had undergone 
medical circumcision, but this effect was not seen in Zambia 
(test for interaction: P = .004), while in Zambia but not in South 
Africa, HSV2 infection was more prevalent among men with 
lower levels of education (test for interaction: P < .001). Effects 
of marital status varied between countries in both sexes. In 
Zambia, men and women who were single had a decreased risk 
of HSV2 infection, while South African women who were single 
had an increased risk (test for interaction: P < .001).
Association Between HSV2 and HIV at the Individual Level
The HIV prevalence in women and men was 27% and 11%, 
respectively, in South Africa and 25% and 13%, respectively, in 
Zambia. Table 2 shows the association between HSV2 and HIV 
at the individual level in men and women. Odds ratios (ORs) are 
adjusted for age and community and then additionally for other 
confounding factors. There was a very strong association, with 
a 6-fold higher odds of HIV infection among HSV2-infected 
individuals in both sexes, even after adjustment for other risk 
factors, including lifetime number of sex partners (adjusted 
OR, 6.66 [95% CI, 6.07–7.31] among women and 6.57 [95% CI, 
5.56–7.77] among men).
Association between HSV2 and HIV at the Community Level
There was substantial variation in HSV2 prevalence between 
communities in both countries. This was particularly so in South 
Africa, where the prevalence varied from 13% to 37% among 
men and from 28% to 74% among women (Supplementary 
Table 4).
Figure  2 shows the association between the prevalences of 
HSV2 and HIV infection at the community level. There was an 
extremely strong linear relationship between the 2 infections, 
overall (ρ  =  0.92; P  <  .001) and separately among men and 
women (Supplementary Figure 1). The overall HIV prevalence 
was always >25% when the HSV2 prevalence was >50%, and it 
was always below about 10% when the HSV2 prevalence was 
below about 30%.
We examined whether the variations in HSV2 prevalence 
could be explained by differences in reported sexual behavior. 
Figure  3 shows the strong association between the commu-
nity HSV2 prevalence and the mean lifetime number of sex 
partners (ρ = 0.58; P = .006). However, when linear regression 
was used to analyze the association between HIV and HSV2 
at the community level, this association remained strong after 
adjustment for mean number of lifetime sex partners (P < .001; 
Supplementary Table 5). The relationship between HIV preva-
lence and mean lifetime number of sex partners was similar and 
is shown in Supplementary Figure 2.
DISCUSSION
This study of nearly 40 000 men and women in 21 urban and 
peri-urban communities confirms the strong association 
between HIV and HSV2 at both the individual and commu-
nity levels. At the individual level, HSV2-infected men and 
women had a roughly 6-fold higher odds of HIV infection than 
HSV2-uninfected individuals, even after allowing for other risk 
factors. At the community level, there was an exquisite linear 
relationship between the 2 infections.
Many previous studies have documented the strong asso-
ciation between these 2 infections at the individual level, and 
this finding has been remarkably consistent across different 
studies and settings [4, 28]. In cross-sectional studies (includ-
ing the current analysis), the direction of causality cannot be 
definitively established, and some or all of the association might 
be explained by an effect of HIV on the acquisition of HSV2 
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infection. However, the HSV2 prevalence increases with age 
much more rapidly and to much higher levels than the HIV 
prevalence, and so it seems likely that HSV2 infection precedes 
HIV acquisition in most cases. Moreover, longitudinal studies 
have shown a strong association between prior HSV2 infec-
tion and acquisition of HIV during follow-up, consistent with a 
direct causal effect of HSV2 on HIV infection [5].
The association between HSV2 and HIV could be con-
founded by sexual risk behavior. Both infections are sexually 
transmitted, so HIV and HSV2 may cluster among individuals 
with larger numbers of sex partners. As in previous studies, we 
continue to find a strong association even after adjustment for 
age, lifetime number of sex partners, and other risk factors, but 
we cannot rule out residual confounding, given (1) the limita-
tions of self-reported data on sexual behavior [5] and (2) net-
work effects making information about lifetime number of sex 
partners insufficient to completely control for confounding [29].
The most definitive test of a causal effect of HSV2 on HIV 
acquisition would be evidence from a randomized trial of an 
effective intervention against HSV2 that shows a reduced inci-
dence of HIV infection. Disappointingly, the 3 trials that have 
directly examined the effects of acyclovir therapy among HSV2-
infected individuals who were either negative or positive for HIV 
showed no effect on HIV infection incidence [18–20]. However, 
subsequent studies have shown that the treatment regimen used 
for HSV2 in these trials was likely insufficiently potent to avert 
the strong biological interaction between the 2 infections [16].
We went on to look at the association between HSV2 and 
HIV at the community level. To our knowledge, the only pre-
vious ecological analysis of this kind was performed as part of 
the Four Cities Study that examined explanations for the differ-
ent HIV epidemics in 2 cities (Cotonou, Benin, and Yaounde, 
Cameroon) with a relatively low HIV prevalence in West 
Africa and 2 high prevalence cities (Kisumu, Kenya, and Ndola, 
Table 2. Association between Herpes Simplex Virus Type 2 (HSV2) Infection and Human Immunodeficiency Virus (HIV) Infection, Overall and by Country
Women Men
Variable HIV Positivity, Proportion (%) ORa (95% CI) aORb (95% CI) HIV Positivity, Proportion (%) ORa (95% CI) aORb (95% CI)
Overall
HSV2 negative 791/11 970 (7) 1 1 368/8149 (5) 1 1
HSV2 positive 5986/14 204 (42) 7.70 (7.08–8.37) 6.66 (6.07–7.31) 909/2629 (35) 6.84 (5.93–7.90) 6.57 (5.56–7.77)
South Africa
HSV2 negative 346/4922 (7) 1 1 169/3996 (4) 1 1
HSV2 positive 2972/7250 (41) 6.20 (5.48–7.03) 5.49 (4.77–6.33) 444/1473 (30) 6.14 (5.00–7.53) 5.58 (4.38–7.12)
Zambia
HSV2 negative 445/7048 (6) 1 1 199/4153 (5) 1 1
HSV2 positive 3014/6954 (43) 8.87 (7.94–9.92) 7.38 (6.52–8.36) 465/1156 (40) 5.58 (4.37–7.12) 7.66 (6.07–9.65)
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio
aAdjusted for age group and community.
bAdjusted for age group, community, lifetime number of sex partners, sexual partners in the past year, audit score, recreational drug use, education level, marital status, nights away from 
home in the past 3 months, socioeconomic status, and, for men, circumcision.
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Figure  2. Community-level association between herpes simplex virus type 2 
(HSV2) prevalence and human immunodeficiency virus (HIV) prevalence.
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Figure 3. Community-level association between lifetime number of sex partners 
and herpes simplex virus type 2 (HSV2) prevalence.
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Zambia) in East and Southern Africa [4, 14]. Interestingly, this 
study found few differences in reported sexual behavior that 
could explain the different epidemics, but it identified 2 biologi-
cal factors, HSV2 infection and male circumcision, that showed 
major differences between the cities with high and those with 
low prevalences [14]. However, the conclusions were limited by 
the small number of communities studied.
With 21 large urban and peri-urban communities, spread 
across 2 countries in Southern Africa with generalized HIV 
epidemics, the HPTN 071 (PopART) study provided much 
greater scope to examine this ecological correlation. The results 
were striking, and we were surprised by the extremely strong 
association between the prevalences of the 2 pathogens at the 
community level, such that the prevalence of HIV could be pre-
dicted almost exactly from the HSV2 prevalence. An important 
question is whether this relationship merely reflects variations 
in sexual behavior between the communities that have a com-
mon effect on the transmission dynamics of the 2 infections or 
whether it reflects a powerful cofactor effect of HSV2 infection 
on HIV acquisition and transmission.
It is likely that both mechanisms play a role in explaining 
the observed associations, and we are unable to quantify the 
importance of each. However, there are 3 reasons why we con-
sider it likely that the biological cofactor effect of HSV2 plays an 
important role. First, although both viruses are sexually trans-
mitted, they have different transmission dynamics. HSV2 is 
much more readily transmitted, has a much higher prevalence, 
is less concentrated in core groups with high rates of partner 
change, and has a different clinical course (a high frequency of 
symptomatic episodes in early infection, followed by long peri-
ods of asymptomatic infection later in life), which likely affects 
the pattern of transmission. It therefore seems implausible that 
confounding by sexual behavior would in itself produce such a 
strong linear relationship between the 2 infections. Second, the 
consistency and strength of the association between HIV and 
HSV2 at the individual level is unusual in HIV epidemiology 
and argues for a biological mechanism. Third, we now have data 
from detailed biological studies demonstrating the strong inter-
action between the viruses at mucosal and cellular levels [16].
If this conclusion is valid, it has important implications for HIV 
epidemiology and control. The cofactor effect of HSV2 is import-
ant not only because of its strength but because HSV2 infection 
is such a prevalent condition. Our study and studies by others 
show that a large proportion of men and women become infected 
with this virus by the age of 35 years in many parts of sub-Saha-
ran Africa [1, 4]. Moreover, many individuals (especially young 
women) acquire their initial HSV2 infection in adolescence or 
early adulthood [2]. Frequent clinical episodes of genital herpes 
during the early years of HSV2 infection are likely to put individ-
uals at high risk of HIV infection during the period when they 
are most likely to be exposed. For these reasons, mathematical 
models have shown that a large proportion of HIV infections may 
be attributable to HSV2 infection in this region [12, 13]. With the 
increasing recognition that a combination of preventive tools will 
be needed to move toward elimination of HIV as a public health 
problem, effective interventions against HSV2, such as the pro-
phylactic or therapeutic vaccines currently under study, may play 
an important role in this struggle [21, 24].
Strengths of our study include the large number of communi-
ties studied across diverse geographical settings, the large sam-
ple of randomly selected adults from each community, and the 
systematic collection of data on a wide range of variables that 
may be risk factors for the infections under study. Limitations 
include the cross-sectional study design, the usual biases in 
self-reported data (especially on sexual risk behavior), and the 
potential for some bias in the study sample, given that some 
individuals randomly selected for inclusion could not be con-
tacted and that men were differentially underrepresented in the 
sample. Both HIV and HSV2 are common in these populations, 
so the ORs presented here are not approximations of risk ratios.
The association between HIV and HSV2 has been known for 
many years but has been relatively neglected since the negative 
results of the acyclovir treatment trials were published [18–20]. Our 
data provide new and compelling evidence of the likely role of HSV2 
in explaining variations in the HIV epidemic between regions and 
communities, as well as the very high incidence of HIV infection in 
some parts of sub-Saharan Africa. If this is true, renewed attention 
is needed to the development and evaluation of effective HSV2 con-
trol measures as tools for HIV prevention and to reduce the signifi-
cant burden of disease associated with this ubiquitous virus.
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